{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"7.10","upperLimit":"8.57","value":"7.75"},{"groupId":"OG001","lowerLimit":"6.67","upperLimit":"7.16","value":"6.93"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"614"},{"groupId":"OG001","value":"598"}],"units":"Participants"}],"title":"All randomized participants"},{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"7.03","upperLimit":"8.51","value":"7.52"},{"groupId":"OG001","lowerLimit":"6.21","upperLimit":"7.06","value":"6.93"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"506"},{"groupId":"OG001","value":"510"}],"units":"Participants"}],"title":"Participants with PD-L1 CPS ≥ 1"},{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"7.03","upperLimit":"9.40","value":"8.31"},{"groupId":"OG001","lowerLimit":"5.55","upperLimit":"6.93","value":"6.14"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"473"},{"groupId":"OG001","value":"482"}],"units":"Participants"}],"title":"Participants with PD-L1 CPS ≥ 5"},{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"7.00","upperLimit":"9.79","value":"8.41"},{"groupId":"OG001","lowerLimit":"5.45","upperLimit":"6.90","value":"5.82"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"285"},{"groupId":"OG001","value":"307"}],"units":"Participants"}],"title":"Participants with PD-L1 CPS ≥ 10"}],"denoms":[{"counts":[{"groupId":"OG000","value":"614"},{"groupId":"OG001","value":"598"}],"units":"Participants"}],"description":"Progression free survival (PFS), defined as the time from randomization to the date of the first documented progressive disease (PD) or death due to any cause, in participants treated with Nivolumab plus Chemotherapy vs Chemotherapy by BICR per RECIST1.1 in participants with PD-L1 CPS ≥ 10, 1, or all randomized subjects. Progreessive disease (PD) is defined as at least a 20% increase in the sum of diameters of target lesions, taking in reference the smallest sum on study that also demonstrated an absolute increase of at least 5 mm. CPS is defined as the number of PD-L1 staining cells (tumor cells, lymphocytes, macrophages) divided by the total number of viable tumor cells, multiplied by 100.","dispersionType":"95% Confidence Interval","groups":[{"description":"Nivolumab + Xelox: Nivolumab 360 mg IV over 30 minutes on Day 1 of each treatment cycle, every 3 weeks + Oxaliplatin 130 mg/m2 IV on Day 1 of each treatment cycle + capecitabine 1000 mg/m2 orally twice daily (ie, 1000 mg/m2 in the morning and 1000 mg/m2 in the evening) on Days 1 to 14 of each treatment cycle, every 3 weeks\n\nNivolumab + Folfox: Nivolumab 240 mg IV over 30 minutes on Day 1 of each treatment cycle, every 2 weeks + Oxaliplatin 85 mg/m2 + leucovorin 400 mg/m2 + fluorouracil 400 mg/m2 IV on Day 1 of each treatment cycle, and fluorouracil 1200 mg/m2 IV continuous infusion over 24 hours (or per local standard) daily on Days 1 and 2 of each treatment cycle, every 2 weeks","id":"OG000","title":"Arm 1: Nivolumab + Chemotherapy (XELOX or FOLFOX)"},{"description":"Chemotherapy (XELOX or FOLFOX): Xelox: Oxaliplatin 130 mg/m2 IV on Day 1 of each treatment cycle + capecitabine 1000 mg/m2 orally twice daily (ie, 1000 mg/m2 in the morning and 1000 mg/m2 in the evening) on Days 1 to 14 of each treatment cycle, every 3 weeks. Folfox: Oxaliplatin 85 mg/m2 + leucovorin 400 mg/m2 + fluorouracil 400 mg/m2 IV on Day 1 of each treatment cycle, and fluorouracil 1200 mg/m2 IV continuous infusion over 24 hours (or per local standard) daily on Days 1 and 2 of each treatment cycle, every 2 weeks. Comparison group to Arm 1.","id":"OG001","title":"Arm 2a: Chemotherapy (XELOX or FOLFOX)"}],"paramType":"MEDIAN","populationDescription":"All randomized participants with available PFS measurements in various subsets","reportingStatus":"POSTED","timeFrame":"From randomization to the date of the first documented progressive disease (PD) per BICR or death due to any cause (up to approximately 10 months)","title":"PFS in Participants Treated With Nivolumab Plus Chemotherapy vs Chemotherapy","type":"SECONDARY","unitOfMeasure":"Months"}